Viridian Therapeutics Gets Double Buy Rating After Roche's Weak TED Results

Jefferies and Wedbush maintain Buy ratings on Viridian Therapeutics as Roche's thyroid eye disease drug shows weaker results than Viridian's veligrotug therapy.